---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-217619"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2024-09-12T23:59:59+00:00"
generated_at: "2026-05-31T05:13:36.890570+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aura reports positive Phase 2 bel-sar results: 80% tumor control, 90% vision preservation

## Summary
- Bel-sar achieved 80% tumor control rate in Phase 3-eligible patients (8/10); complete cessation of growth post-treatment.
- Visual acuity preserved in 90% of 10 patients; 80% had high-risk tumors near fovea/optic disc.
- No treatment-related serious adverse events; mild Grade 1 ocular AEs self-limited, resolved in median 6 days.
- FDA agreed under Special Protocol Assessment for Phase 3 CoMpass trial; enrollment ongoing.
- Virtual investor event today at 8:00 am ET featuring key opinion leaders.

## SEC filing metadata
- accession: 0001193125-24-217619
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2024-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000119312524217619/0001193125-24-217619-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000119312524217619/d886516d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-217619
- JSON: https://secwatch.observer/filing/0001193125-24-217619.json
- Plain text: https://secwatch.observer/filing/0001193125-24-217619.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.